Neuroblastoma (NBL) is a tumor of the sympathetic nervous system arising from the neural crest. It is therefore composed of undifferentiated neuroectodermal cells and the most common site of localization is the adrenal medulla (as reviewed by Brodeur, 1990) . It is the third most common pediatric cancer and the one most often seen in newborns (reviewed in Maris and Matthay, 1999) . NBL is characterized by vast heterogeneity, ranging from spontaneous regression to aggressive malignant behavior often with a fatal outcome. A particularly aggressive subtype of NBLs is genetically characterized by amplification of the MYCN oncogene and of chromosome 1p deletions (for a review, see Maris and Matthay, 1999) . Gain of parts of the long arm of 17q (17q gain) has also been shown to be a characteristic feature of the aggressive subtype (Lastowska et al., 1997; Abel et al., 1999; Bown et al., 1999) . The frequent 1p-deletion in clinically advanced tumors implies that the 1p-region contains at least one gene (denoted TSG; tumor suppressor gene; NBS, OMIM 256700) that is prone to inactivation in NBL tumors.
Our group and others have tried to narrow down the consensus region of the NBS locus (Caron et al., 1995 Maris et al., 1995 Maris et al., , 2001 Martinsson et al., 1995 Martinsson et al., , 1997 White et al., 1995 White et al., , 2001 Ichimiya et al., 1999; Bauer et al., 2001; Ejeska¨r et al., 2001; Spieker et al., 2001) . Our previous efforts to delimit the 1p-region most commonly deleted in NBL tumors, primarily of Scandinavian origin have identified a shortest region of overlap (SRO) of deletions in our material of approximately 25 cM between distal marker D1S80 and proximal marker D1S244 on the short arm of chromosome 1 (Martinsson et al., 1995 (Martinsson et al., , 1997 . Subsequent 1p-LOH studies of both NBLs and germ cell tumors identified a 5 cM combined SRO of deletion for these tumor types defined distally and proximally by markers D1S508 and D1S244, respectively (Ejeska¨r et al., 2001) .
Further support for the localization of a TSG to this region was obtained when a homozygously deleted region at 1p36.2-3 was found in an NBL cell line (Ohira et al., 2000) . This deleted region maps in the proximal part of the NBL consensus deletion region defined by us, close to the D1S244 marker, and it is delimitated by the genes UBE4B/UFD2 (ubiquitination factor E4B -homologous to yeast gene) and PEX14 (peroxisomal biogenesis factor 14; OMIM 601791), with KIF1B (kinesin superfamily protein member 1B; OMIM: 605995), DFFA (DNA fragmentation factor, 45 kDa, alpha; OMIM: 601882), PGD (phosphogluconate dehydrogenase; OMIM: 172200) and CORT (cortistatin, OMIM 602780) in between (Figure 1a 9.4 9.5 9.6 9.7 9.8 9.9 Mb from 1pter Martinsson et al., 1995 Ohira et al., 2000 ICAT 9.2 D1S244 UBE4B KIF1B PGD CORT DFFA PEX14
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Neuroblastoma tumor suppressor candidate region C Krona et al just distal of this region is the ICAT (beta-catenin interacting protein) gene. Several of these genes are likely to be involved in cellular proliferation and/or differentiation and may constitute excellent candidates for being a tentative NBS gene. We have previously presented data on the CORT and DFFA genes performed on a set of NBL tumors (Ejeska¨r et al., 2000; Abel et al., 2002) . In this paper, we have analysed the remaining five genes in the region in a set of NBL tumors. The complete coding region of UBE4B/UFD2, PGD, PEX14, and ICAT have now also been determined in a set of NBL tumors using direct DNA-sequencing, together with most of the KIF1B gene. Thus, we have in detail studied the genes in the combined region as suggested by Ohira et al. (2000) and by us (Martinsson et al., 1995) in a tumor set separate from that studied by Ohira et al. Also, the expression of the genes in NBL tumors was analysed. Several new polymorphisms in the genes are presented, both in coding and in noncoding regions. One true mutation in the UBE4B/UFD2 gene was detected in a stage 3 NBL with a fatal outcome. This fact and the very low expression of UBE4B/UFD2 in high-stage tumors are indicative of UBE4B/UFD2 as a player in NBL development and/or progression.
DFFA is a gene coding for the protein DFF45 and the short splice variant DFF35. Mutation analysis data for this gene have been presented earlier by our group (Abel et al., 2002) . DFF45 must be cleaved by caspase-3 and dissociate from the DFF40/DFF45 complex for the 40-kDa subunit of DNA fragmentation factor to induce DNA fragmentation and chromatin condensation during apoptosis (Liu et al., 1997 (Liu et al., , 1998 . The full-length variant of DFF45 also has an important function as a chaperone for DFF40 (Sakahira et al., 1999 (Sakahira et al., , 2000 . In two tumors one rare allele variant, causing a nonpolar to an uncharged polar amino-acid exchange (I69T), could be detected in the coding region of DFFA. This region, where the exchange occurs, is predicted to be involved in the binding between DFF45 and DFF40 (Abel et al., 2002) This amino-acid substitution might disrupt the ability of DFF45 to help DFF40 to acquire its final, appropriately folded form. Cells with this mutation can consequently have a reduced ability to induce apoptotic mechanisms such as DNA fragmentation and chromatin condensation.
Selective protein degradation through the ubiquitin/ proteasome system plays an important role in eukaryote cellular regulation. It is also essential for protecting cells against environmental stress because of its role in the elimination of aberrant proteins generated under normal and, in particular, stress conditions (Hochstrasser, 1996) . Efficient multi-ubiquination needed for proteasomal targeting of a protein requires the conjugation factor E4 of which family UBE4B/UFD2 is a member (Koegl et al., 1999) . In yeast, the E4 homologue, UFD2, is linked to cell survival under stress conditions. It is likely to mediate the degradation of stress-induced aberrant proteins. This makes UBE4B/UFD2 a conceivable candidate TSG based on its functional characteristics as well as the position of the gene in a NBL hot spot region. The gene structure of UBE4B/UFD2 as derived from the alignment of the reference sequence NM_006048 with the UCSC (URL: http//genome.ucsc.edu) chromosome 1 draft sequence is shown in Figure 1b . The gene consists of a coding sequence of 3909 bases distributed over 28 exons. The short exon 1 sequence was not aligned to the UCSC draft sequence Ohira et al. (2000) , is indicated by a dark shaded box, while the NBL SRO as defined by our group (Martinsson et al., 1995) is shown as a light gray box. The region includes the genes UBE4B/UFD2, KIF1B, DFFA, PGD, CORT and PEX14. ICAT is located just distal of the region. Arrows indicate the transcriptional direction of the genes. The scale in the top is the approximate distance from the 1p-terminal, in megabase pairs. The study was performed on tumor samples obtained from patients with the diagnosis NBL mainly from the Scandinavian countries. The tumors were staged according to the International NBL Staging System criteria (INSS; Brodeur et al., 1993 Brodeur et al., , 1988 . Clinical data on patients have been published earlier (Martinsson et al., 1995; Abel et al., 2002) . Genomic DNA was extracted from frozen (À701C) tumor tissue, and in some cases also from corresponding peripheral blood, according to standard procedures. (b) Genomic structures of the genes UBE4B/UFD2, PGD, PEX14, and ICAT with schematic representations of exonintron structures together with the detected deviations from the reference sequences. Shaded boxes represent the coding regions and dark boxes represent the 5 0 -and 3 0 -untranslated regions of the genes. The intron sizes are indicated in the figure in kilobase pairs. Information on sequences for PCR primers used, annealing temperatures, and data on the number of analysed tumor and control samples for each exon are available on request. Initially, 23 tumors of all different stages were chosen for sequencing of UBE4B/UFD2, PEX14, PGD, and ICAT. Stages 1, 2a, and 4S were represented by one tumor each, while advanced stages 3 and 4 were represented by 10 and 9 tumor cases, respectively. After this initial screening some exons that showed deviations relative to reference sequence was further analysed in an additional set of tumors. For several exons, approximately 40-100 tumor samples were analysed in total (Tables  1 and 2 ). Control samples, derived from normal blood, were included in the sequencing of all exons. For some exons, where deviations were detected, an additional number of controls were sequenced (see Tables 1 and 2 ); in confirmation cases approximately 100 control samples were analysed. An initial screening was performed on most of the exonic sequences from the KIF1B gene. Since this revealed no variations from the reference sequence, further analysis of this gene was not undertaken (data not shown). The changes found in the coding sequences of the genes by DNA sequencing are denoted by lines connecting the sequence deviations to the corresponding sites in the figure derived by in silico mapping using the respective reference sequences. Changes in coding sequences are written as the example (1713G>C; L571F) with the A of the initiator Met codon denoted nucleotide +1. The amino acids are represented by their single letter code with the amino acid in the reference sequence to the left and the alternative amino acid, deduced from the translation of the sequenced fragment, to the right with the position of the substitution in the protein sequence in between. In the cases where the change in nucleotide sequence is not silent at protein level, the type of amino-acid change is marked; np, nonpolar; up, uncharged polar; b, basic. 1439+1G>C represents a mutation in the donor splice site of exon 9 in UBE4B/UFD2. The polymorphism in the 3'UTR region, 80 bases after exon 28 of UBE4B/UFD2, has a previous record in dbSNP (rs1046277). The polymorphism in exon 3 of P6D has two previous records in dbSNP (rs49887/2070193) (PEX14) Neuroblastoma tumor suppressor candidate region C Krona et al when NM_006048 was used for the BLAT search. Instead, the cDNA AB028839 was used to define the boundaries of these 24 nucleotides after the initiation codon.
Sequence analysis identified a few polymorphic changes in UBE4B/UFD2 (Tables 1 and 2 ). One of them, which was located in the 3 0 UTR of the gene (c.3909+80T>C; where c.1 represents the first base of Neuroblastoma tumor suppressor candidate region C Krona et al the initiation codon and bases after a 'À' or a '+' sign denote nucleotide distance upstream or downstream, respectively, from that base in the genomic sequence; nomenclature described by Antonarakis, 1998) , has previously been reported in the NCBI dbSNP (rs1046277). One conservative amino-acid substitution was observed in exon 13 (c.1713G>C; L571F) in heterozygous form in 2/94 tumors. This variation was also observed in 2/90 control individuals. Two nucleotide transitions were observed in exon 22. Both were silent at protein level and the first (c.2952T>C; S984S) was observed also in the control in heterozygous form. Another silent transition in exon 26 (c.3594A>G; T1198T) was detected in 3/56 tumors, one of them in homozygous form and the other two in heterozygous form.
A somatic heterozygous mutation was observed in the splice donor site of exon 9 (c.1439+1G>C) in 1/89 tumors (Case St131, a stage 3 tumor with a fatal outcome). This change from the invariant bases GT to CT was neither found in the normal DNA of this patient nor in any of the 192 control chromosomes analysed (Figure 2) , and thus constitutes a true mutation. This change of the evolutionary conserved splice site in one patient is likely to elicit erroneous intron inclusion. A premature termination codon is then introduced only a few bases after exon 9, and the function of the gene will most likely be abolished since the C-terminal domain is highly conserved between proteins of the UFD2 family in different species (Figure 2b, c) . It is postulated that binding of UFD2 proteins to ubiquitin-protein conjugates is mediated by this conserved domain (Koegl Column 2, exon from which the position in the intronic sequence is counted; Column 3, variation in noncoding sequence n nucleotides before (À) or after (+) the designated position in the cDNA. Positive numbers starting from the G of the donor site invariant GT, negative numbers starting from the G of the acceptor site invariant AG a Published: dbSNP:rs1046277
Neuroblastoma tumor suppressor candidate region C Krona et al et al., 1999). However, it is also possible that this point mutation, changing GT to CT, will activate a cryptic splice site or cause the exclusion of the entire exon 9 together with introns 8 and 9 if the spliceosome fails to recognize this sequence as an exon. In exon 24 a nonconservative germ line deviation (c.3225G>C; Q1075H), causing an uncharged polar amino acid to be replaced by a basic amino acid, was observed in heterozygous form in 3/86 tumors. It was also detected in heterozygous form in 2/93 control individuals. Even though this variation could represent a polymorphism, we cannot rule out the possibility that the control from blood) , homozygous G/G. Lower panel: amplified constitutional DNA from control Q392 (from blood), homozygous G/G. For mutation, analysis was performed as follows: primers for the coding sequences of the genes were designed on the basis of the in silico mapping and the UCSC Genome Browser, December 2001 chromosome 1 draft sequence. They were purchased from Life Technologies (www.invitrogen.com; Life Technologies, Inc. Gaithersburg, MD, USA). For DNA-sequencing, the PCR products were purified with ExoSAP-IT (USB, Corp., Cleveland, OH, USA). The sequencing reactions were made using the ABI PRISM Big Dye Terminator Cycle Sequencing Ready Reaction Kit (Applied Biosystems, Foster City, CA, USA) according to ABI protocols. Sequencing was performed using an ABI PRISM 3100 DNA Sequencer (Applied Biosystems). Sequences derived from the tumor samples were compared to the corresponding sequence from DNA of a normal blood donor or a reference sequence derived from NCBI (URL: http:// www.ncbi.nlm.nih.gov. In the cases where a deviation from the reference was observed, it was confirmed through resequencing from the opposite direction. (b) Schematic representation of amplification products from cDNA samples amplified with primers located in exons 9 and 10, respectively. One short fragment is amplified if the transcript is normally spliced, while a much longer fragment is amplified if splicing of the exon 9 donor site to the exon 10 acceptor site does not occur and intron retention is the result. The gene structure of PGD as a result of a comparison between the reference sequence NM_002631 and the cDNA BC000368 is shown in Figure 1b . As in the case with UBE4B/UFD2, a cDNA with a longer 5 0 UTR than the reference sequence had to be used to make the alignment of the first bases of the coding sequence of PGD to the UCSC draft sequence possible. The coding sequence of the gene consists of 1458 bases distributed over 13 exons. One striking finding from the in silico mapping of PGD was that the donor splice site of exon 6 was GC instead of the consensus GT in all sequenced samples including the control samples. This is also the case in the reference sequence NM_002631. The disposition of a noncanonical splice site, that is a GC-AG pair instead of the canonical dinucleotides GT and AG as donor and acceptor sites, respectively, is well characterized and has been estimated to occur in 0.5-1.1% of the total splice site pairs in the genome (Burset et al., 2000; Thanaraj and Clark, 2001; Clark and Thanaraj, 2002) . Sequence analysis demonstrated seven deviations from the reference sequence NM_002631 (Tables 1 and 2 ). All were either polymorphic changes or errors in the reference sequence. No nonpolymorphic changes were observed in PGD, which indicates that this gene is not involved in the pathogenesis of NBL. This is in accordance with the fact that PGD does not have any characteristics of a classical TSG.
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In silico mapping of PEX14 by alignment of the reference sequence NM_004565 to the UCSC chromosome 1 draft sequence displayed a gene consisting of nine different exons (Figure 1b) . The gene extends over a large genomic area (approximately 150 000 bp) and thus has large introns. The mutation analyses of PEX14 revealed four variations in the coding sequences, as well as two alterations in intronic sequences close before and after exons. All coding alterations occurred in the third base of a coding triplet and they did not cause any amino-acid exchange. An overview of the results from mutation analysis of PEX14 is shown in Tables 1 and 2 , and in Figure 1b . Linkage disequilibrium was observed between polymorphisms in PEX14 where c.156T>C; F52F in exon 3 was shown to link to the variation c.37À74C>T, located 74 bases upstream of exon 2 and approximately 50 kb from exon 3.
The ICAT gene, which is located just distal to the homozygously deleted region but within the NBL SRO, was screened for mutations based on the candidate properties of the gene. ICAT may, according to Tago et al. (2000) , interfere with the interaction between betacatenin and TCF-4, and thereby act as a negative regulator in the Wnt signaling pathway. This signaling has an important role in both embryonic development and tumorigenesis (for reviews, see Cadigan and Nusse, 1997; Miller et al., 1999; Peifer and Polakis, 2000) . By its function as a negative regulator of Wnt signaling, inactivation of ICAT could cause inappropriate activation of the target genes in the signaling pathway. ICAT could therefore act as a TSG in the development of the embryonic cells that eventually will become NBL tumor cells. Alignment of ICAT mRNA NM_020248 to the UCSC chromosome 1 draft sequence displayed a gene with three exons in the coding region, which in total is 246 bp long. Figure 1b shows the gene structure of ICAT. Mutation analysis performed for ICAT exons 1-3 disclosed no deviations from the control DNA or from the NCBI reference sequence in our set of NBL tumors.
We have analysed CORT in detail earlier (Ejeska¨r et al., 2000) and no mutations were detected in this gene. Also, KIF1B sequences analysed revealed no significant changes. Thus, we could find no evidence that any of these genes are involved in NBL tumorigenesis.
RT-PCR expression analysis of UBE4B/UFD2 was performed and compared with RT-PCR of the genes DFFA and GAPDH from the same tumor samples (Figure 3a) . The expression study of UBE4B/UFD2 in NBL tumors followed the same expression pattern as for DFFA with a markedly lower expression in the high stage tumors. Our study regarding the expression status of exon 7 in UBE4B/UFD2 clearly indicated that the cDNA AB028839 is correct with respect to the sequence corresponding to exon 7 in NM_006048. Thus, exon 7 is not included in the transcript in the cases analysed (Figure 3b ). Our observation of reduced expression patterns of DFFA and UBE4B/UFD2 in high-stage tumors thus confirms the study by Ohira et al. (2000) , in which they observed a significantly higher expression level of these genes in favorable stage 1 tumors than in unfavorable tumors with MYCN amplification.
What are the evidences for a TSG in the region? Even though all the known genes in the region found to be homozygously deleted in a NBL cell line have been screened for mutations, there is still a possibility that there are genes in the region that are not yet annotated. It should also be noted that we have primarily analysed coding regions of the genes in this study. The promoter regions of the genes have neither been sequenced nor investigated for epigenetic inactivation by promoter methylation. Also, intronic sequences of the region, the first exon of PEX14 and some of the exons of KIF1B were not investigated. However, it does not seem likely that all of the inactivating mutations of a gene should be located in regulating sequences. If one of the genes in the region was involved in the development of NBL tumors, we would have expected to observe a higher frequency of inactivating mutations in the coding sequence.
At least two alternative NB tumor suppressor loci have been suggested in the 1p35-36 region. LOH studies of tumors from patients in the Netherlands and Belgium have demonstrated distinct types of SRO in tumors with or without MYCN amplification (Caron et al., 1995 . MYCN-amplified NBLs were associated with large 1p deletions extending from 1p35-36.1 to the telomere. In the MYCN single copy tumors, however, the SRO was restricted to 1p36.2-3 and the lost alleles were preferentially of maternal origin suggesting paternal imprinting of the locus. Several LOH studies including a large number of NBL tumors have defined 1p36.3 as the region to be consistently deleted with varying SROs (Ichimiya et al., 1999; Bauer et al., 2001; Maris et al., 2001; White et al., 2001) . The absence of mutations in the coding regions of the investigated genes is consistent with the observation by Caron et al. (1995 Caron et al. ( , 2001 ) that a deletion of one allele might be supplemented by epigenetic mechanisms on 1p36.2-3 that inactivate the remaining TSG allele. Also, other investigators have suggested alternative TSG locations (Ichimiya et al., 1999; Bauer et al., 2001; Maris et al., 2001; White et al., 2001) . Therefore, it is a possibility that the homozygously deleted region in a NBL cell line, is a secondary effect of tumorigenesis and that an NBL TSG is located more distal on 1p.
In conclusion, no solid evidence supporting the hypothesis of any of the seven investigated genes in this 500 kb region on 1p36.2 functioning as an NBL TSG was found. Still, there are a number of intriguing sequence changes, which together with the reduced expression pattern of these genes (DFFA and UBE4B/ UFD2) raise the question of whether any or both of these genes are involved in a pattern of gene disruptions and transcriptional regulation on 1p36.2-3 that collaborates in the task of tumor development or further progression along the path of malignant changes from normal cellular behavior through unknown mechanisms.
We would, however, like to stress that several lines of evidence support a role for UBE4B/UFD2 in the NBL development. (i) It is deleted in all NBL cases with a deletion as tested by us, that is, it is located in the SRO region. (ii) It is disrupted by homozygous loss in the NBL cell line case presented by Ohira et al. (2000) . (iii) We have detected a mutation in one primary stage 3 NBL tumor with a fatal outcome. (iv) The function of UBE4B/UFD2 is well in line with that of a tumor suppressor gene (see discussion above). (v) UBE4B/ UFD2 has a marked stage-specific expression pattern, in general with a very low or even absent expression in high-stage/poor outcome tumors relative to the strong expression of the low-stage/favorable outcome tumors. (vi) An additional interesting fact is that a strongly homologous gene to UBE4B/UFD2, that is, UBE4A, is one of a few genes mapped to the 2-5 cM consensus 11q-deletion region shown in a group of NBLs (Guo et al., 1999 (Guo et al., , 2000 John M Maris, personal communication) . This group that consists of NBLs without MYCN amplification and with a poor prognosis could be a 'complementary' group to those discussed in this paper; 1p-deletion generally goes with MYCN amplification in the NBLs discussed in this paper. One could therefore speculate that a screwed expression of either UBE4B/ UFD2 (located in 1p36.3) or UBE4A (in 11q23.3) is somehow an important step in NBL development. The data prompt for further study of the role of UBE4B/ UFD2, for example, in experimental animal models and such studies will be performed. (Abel et al., 2002) . This was done in order to make a comparison between the expression patterns of the two genes in the tumor samples. The expression of UBE4B/UFD2 was tested by reverse transcriptase-PCR (RT-PCR) with a forward primer located in exon 3: 5 0 -CTCTCAG-CAGCTCGCCCTCTA-3 0 and a reverse primer in exon 5: 5 0 -TTCCTGAATCCACATCCACCTG-3 0 . This generates a cDNA fragment of 126 bp and, theoretically, a genomic DNA fragment of approximately 6000 bp. (b) RT-PCR expression analysis of exon 7 in UBE4B/UFD2. The expression of the sequence corresponding to exon 7 in NM_006048 was investigated by using two primer pairs, I and II, located in exons 6 and 8 and cDNA from tumors 1-4. Tumors 1 and 2 are stage 1 NBLs, tumor 3 is a stage 3 NBL and tumor 4 is a stage 4 NBL. The expected sizes of the PCR products are 206 and 311 bp for primer pairs I and II, respectively, assuming that exon 7 is not included in the transcript. If exon 7 had been expressed, PCR products of 593 and 698 bp would have been amplified with the same primer pairs. The forward primers were located in exon 6 with the sequences: IF (5 0 -GAAATCTCTTGC-TAAACACTG-3 0 ) and IIF (5 0 -TAATGGAAGTGCTAAT-GATG-3 0 ) respectively. They were used in RT-PCR amplification reactions together with a common reverse primer located in exon 8: R (5 0 -TCCAACTCGGTCGAAACACTC-3 0 )
